Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

• DOI: 10.3389/fimmu.2023.1276295
• Publication Date: 2023-10-13T07:16:26Z
• Authors: Yasa Gul Mutlu; Sureyya Yıgıt Kaya; Senem Maral; Elif Melek; Zafer Baslar; Leylagul Kaynar; Omur Gokmen Sevindik
• Keywords: Immunology; CNS Involvement; Elranatamab; RC581-607; 3. Good health; BCMA; multiple myeloma; 03 medical and health sciences; CNS involvement; 0302 clinical medicine; bispecific Ab; Bispecific Ab; Immunologic diseases. Allergy; Multiple Myeloma

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.